
Keywords: آمار; Psoriasis; psoriatic arthritis; autoantigens; IL-17; IL-23; secukinumab; ixekizumab; brodalumab; tildrakizumab, guselkumab, and risankizumab; ADAMTSL5; A disintegrin-like and metalloprotease domain containing thrombospondin type 1 motif-like 5; AMP; Antim